Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1354-1359

  Kline, Justin ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

B7 H1; PD L1; PD1; programmed death 1; programmed death ligand 1; T cell regulation; tumor immune escape; tumor immunity

Indexed keywords

CORTICOSTEROID; CT 011; FLUOROURACIL; FOLINIC ACID; INFLIXIMAB; IPILIMUMAB; MDX 1106; MONOCLONAL ANTIBODY; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTHROPATHY; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PRURITUS; REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 79952775415     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol (1989) 143(8):2714-2722. (Pubitemid 19260086)
2. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 366(6450):76-79. (Pubitemid 23345240)
3. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259(5093):368-370. (Pubitemid 23055679)
4. Schwartz RH: T cell anergy. Annu Rev Immunol (2003) 21: 305-334. (Pubitemid 37174534)
5. Fallarino F, Ashikari A, Boon T, Gajewski TF: Antigen-specifc regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells. Int Immunol (1997) 9(9):1259-1269. (Pubitemid 27389008)
6. Driessens G, Kline J, Gajewski TF: Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 229(1):126-144.
7. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C et al: Effcacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21(8):1712-1717.
8. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfeld W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155-164.
9. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16(3):1042-1048.
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
11. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 23(25):6043-6053.
12. Beck KE, Blansfeld JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte- associated antigen 4. J Clin Oncol (2006) 24(15):2283-2289. (Pubitemid 46630658)
13. Blansfeld JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA et al: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 28(6): 593-598. (Pubitemid 41533093)
14. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF: PD-l1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 64(3):1140-1145. (Pubitemid 38176921)
15. Zhang L, Gajewski TF, Kline J: PD-1/PD-l1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 114(8):1545-1552.
16. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA (2002) 99(19):12293-12297.
17. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O et al: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 9(5):562-567. (Pubitemid 36597102)
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med (2002) 8(8):793-800.
19. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfeld EA, Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 170(3):1257-1266. (Pubitemid 36139491)
20. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA (2004) 101(49): 17174-17179. (Pubitemid 39627793)
21. Thompson RH, Dong H, Kwon ED: Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res (2007) 13 (2 Pt 2):709S-715S.
22. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T et al: Programmed cell death 1 ligand 1 and tumor-infltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA (2007) 104(9):3360-3365. (Pubitemid 46364164)
23. Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 11(11):3887-3895.
24. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 8(5):765-772. (Pubitemid 26148299)
25. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25(21):9543-9553. (Pubitemid 41507854)
26. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11(2):141-151. (Pubitemid 29428807)
27. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH: A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 202(2):231-237. (Pubitemid 41043819)
28. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192(7):1027-1034.
29. Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 5(12):1365-1369.
30. Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C: PD-L1 is induced in hepatocytes by viral infection and by interferon-and-and mediates T cell apoptosis. J Hepatol (2006) 45(4):520-528. (Pubitemid 44307379)
31. Mazanet MM, Hughes CC: B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol (2002) 169(7):3581-3588.
32. Zang X, Allison JP: The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res (2007) 13 (18 Pt 1):5271-5279. (Pubitemid 47510350)
33. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA: Tumor antigen-specifc CD8 T cells infltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114(8): 1537-1544.
34. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L et al: B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 185(5):2747-2753.
35. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439(7077):682-687. (Pubitemid 43237609)
36. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z et al: PD-1 expression on HIV-specifc T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 443(7109):350-354. (Pubitemid 44435155)
37. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH: PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 206(13):3015-3029.
38. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL et al: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 63(19): 6501-6505. (Pubitemid 37255203)
39. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167-3175.
40. Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CG, McDermott DF, Lawrence DP, Wolchok JD, Topalian SL, Lowy I: Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced, refractory malignancies. Proc Am Soc Clin Oncol (2010) 28(15 Suppl):Abs 2506.
41. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 14(10): 3044-3051.
42. Rotem-Yehudar R, Armand P, Devine S, Fay JW, Hosing C, Mapara MY, Campagnero E, Uberti JP, Avigan D, Ballen KK, Winter JN et al: The humanized anti-PD-1 antibody, CT-011, increases specifc CD4+ effector/memory and memory T lymphocytes in patients with diffuse large B cell lymphoma (DLBCL) following autologous stem cell transplantation (AuSCT). ASH Annual Meeting and Exposition (2009):1-238.
43. Chu F, Foglietta M, Qin H, Sharma R, Yi Q, Rodionov G, Rotem-Yehudar R, Neelapu S: In vitro and in vivo effects of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab against human B-cell lymphomas. ASH Annual Meeting and Exposition (2009):Abs 724.
44. Curran MA, Montalvo W, Yagita H, Allison JP: PD-1 and CTLA-4 combination blockade expands infltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275-4280.